[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100547898":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":208,"collaborators":20,"id":210,"slug":211,"hasResults":212,"nctId":213,"briefTitle":214,"officialTitle":215,"acronym":20,"eligibilityCriteria":216,"healthyVolunteers":212,"sex":217,"minAge":218,"maxAge":219,"enrollmentInfo":220,"targetDuration":20,"studyType":223,"phases":224,"briefSummary":226,"conditions":227,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":233,"completionDateStruct":235,"leadSponsor":237,"locationsCount":238},{"fullName":5,"class":6},"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TQB3107 tablets","EXPERIMENTAL","Dosing regimen 1 (20\u002F28): 28 days per cycle (4 weeks), the medication is administered once daily for 5 consecutive days per week, followed by a 2-day break. The initial dose is a single fasting dose of C0, with a subsequent 7-day observation period.\n\nDosing regimen 2 (12\u002F28): every 28 days per cycle, with intermittent dosing.",[13],"Drug: TQB3107 Tablets",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","TQB3107 Tablets","TQB3107 Tablets is a selective target inhibitor.",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"ZhiMing Li, Doctor","CONTACT","13719189172","lzmsysu@163.com",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"HuiLai Zhang, Doctor","18622221228","zhlwgq@126.com",[32,48,62,77,92,107,122,137,152,167,185,197],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Sun Yat-sen University Cancer Cen","RECRUITING","Guangzhou","Guangdong","510060","China","CN",{"type":41,"coordinates":42},"Point",[43,44],113.25,23.11667,{"lat":44,"lon":43},[47],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"facility":49,"status":34,"city":50,"state":36,"zip":51,"country":38,"countryCode":39,"cosmosGeoPoint":52,"geoPoint":56,"contacts":57},"The Fifth Affiliated Hospital Sun Yat-sen University","Zhuhai","519000",{"type":41,"coordinates":53},[54,55],113.56778,22.27694,{"lat":55,"lon":54},[58],{"name":59,"role":24,"phone":60,"phoneExt":20,"email":61},"MingYuan Chen, Doctor","13903052650","chmingy@mail.sysu.edu.cn",{"facility":63,"status":34,"city":64,"state":65,"zip":66,"country":38,"countryCode":39,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"The Affiliated Hospital of Chengde Medical College","Chengde","Hebei","67000",{"type":41,"coordinates":68},[69,70],117.95883,40.9519,{"lat":70,"lon":69},[73],{"name":74,"role":24,"phone":75,"phoneExt":20,"email":76},"ZhiHua Zhang, Doctor","15633142905","zzhangzhihua@163.com",{"facility":78,"status":34,"city":79,"state":80,"zip":81,"country":38,"countryCode":39,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Harbin Medical University Cancer Hospital","Harbin","Heilongjiang","150081",{"type":41,"coordinates":83},[84,85],126.65,45.75,{"lat":85,"lon":84},[88],{"name":89,"role":24,"phone":90,"phoneExt":20,"email":91},"QingYuan Zhang, Doctor","13313612989","sy86298276@163.com",{"facility":93,"status":34,"city":94,"state":95,"zip":96,"country":38,"countryCode":39,"cosmosGeoPoint":97,"geoPoint":101,"contacts":102},"Hunan Cancer Hospital","Changsha","Hunan","410013",{"type":41,"coordinates":98},[99,100],112.97087,28.19874,{"lat":100,"lon":99},[103],{"name":104,"role":24,"phone":105,"phoneExt":20,"email":106},"YaJun Li, Doctor","19918803330","liyajun@hnca.org.cn",{"facility":108,"status":34,"city":109,"state":110,"zip":111,"country":38,"countryCode":39,"cosmosGeoPoint":112,"geoPoint":116,"contacts":117},"The First People's Hospital Of Changzhou","Changzhou","Jiangsu","213000",{"type":41,"coordinates":113},[114,115],119.95401,31.77359,{"lat":115,"lon":114},[118],{"name":119,"role":24,"phone":120,"phoneExt":20,"email":121},"WeiYing Gu, Doctor","0519-68871093","guweiying@czfph.com",{"facility":123,"status":34,"city":124,"state":125,"zip":126,"country":38,"countryCode":39,"cosmosGeoPoint":127,"geoPoint":131,"contacts":132},"Shandong Medical And Pharmaceutical University Hospital","Binzhou","Shandong","256699",{"type":41,"coordinates":128},[129,130],118.01667,37.36667,{"lat":130,"lon":129},[133],{"name":134,"role":24,"phone":135,"phoneExt":20,"email":136},"Na Gao, Doctor","15966356316","gn2882155@163.com",{"facility":138,"status":34,"city":139,"state":140,"zip":141,"country":38,"countryCode":39,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Fudan University Shanghai Cancer Center","Shanghai","Shanghai Municipality","200032",{"type":41,"coordinates":143},[144,145],121.45806,31.22222,{"lat":145,"lon":144},[148],{"name":149,"role":24,"phone":150,"phoneExt":20,"email":151},"Rong Tao, Doctor","13651603660","hkutao@hotmail.com",{"facility":153,"status":34,"city":154,"state":155,"zip":156,"country":38,"countryCode":39,"cosmosGeoPoint":157,"geoPoint":161,"contacts":162},"West China Hospital，Sichuan University","Chengdu","Sichuan","610041",{"type":41,"coordinates":158},[159,160],104.06667,30.66667,{"lat":160,"lon":159},[163],{"name":164,"role":24,"phone":165,"phoneExt":20,"email":166},"LiQun Zou, Doctor","18980601027","hxlcyxy@163.com",{"facility":168,"status":34,"city":169,"state":155,"zip":170,"country":38,"countryCode":39,"cosmosGeoPoint":171,"geoPoint":175,"contacts":176},"The Affiliated Hospital of Southwest Medical University","Luzhou","646000",{"type":41,"coordinates":172},[173,174],105.42575,28.8903,{"lat":174,"lon":173},[177,181],{"name":178,"role":24,"phone":179,"phoneExt":20,"email":180},"XiaoMing Li, Doctor","13700986866","LXM6358@21.com.cn",{"name":182,"role":24,"phone":183,"phoneExt":20,"email":184},"Qing Peng, Doctor","15984007875","pq9712118@163.com",{"facility":186,"status":34,"city":187,"state":188,"zip":189,"country":38,"countryCode":39,"cosmosGeoPoint":190,"geoPoint":194,"contacts":195},"Tianjin Municipality Locations","Tianjin","Tianjin Municipality","300060",{"type":41,"coordinates":191},[192,193],117.17667,39.14222,{"lat":193,"lon":192},[196],{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},{"facility":198,"status":199,"city":200,"state":201,"zip":202,"country":38,"countryCode":39,"cosmosGeoPoint":203,"geoPoint":207,"contacts":20},"The First Affiliated Hospital, Zhejiang University School of Medicine","WITHDRAWN","Hangzhou","Zhejiang","310000",{"type":41,"coordinates":204},[205,206],120.16142,30.29365,{"lat":206,"lon":205},{"type":209,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100547898","phase-1-a-clinical-study-of-tqb3107-tablets-in-patients-with-malignant-tumors-100547898",false,"NCT06413953","A Clinical Study of TQB3107 Tablets in Patients With Malignant Tumors","A Phase I Clinical Study of Tolerability and Pharmacokinetics of TQB3107 Tablets in Patients With Malignant Tumors","Inclusion Criteria:\n\n* 18 years ≤ age≤ 75 years (calculated from the date of signing the informed consent); Score 0\\~1 point, estimated survival ≥ 3 months；\n* Advanced malignant tumor；\n* The major organs are functioning well；\n* Negative serum pregnancy test within 7 days prior to the first dose and must be a non-lactating subject, female and male subjects of childbearing potential should agree to use contraception throughout the study and for 6 months after the study ends;\n* Subjects voluntarily participated in this study, signing the informed consent form and demonstrating good compliance.\n\nExclusion Criteria:\n\n* Hematologic malignancy has or is suspected to involve the central nervous system, or primary central nervous system lymphoma;\n* Received any anti-cancer therapy such as major surgery, chemotherapy and\u002For radiotherapy, immunotherapy, or targeted therapy within 4 weeks prior to the first dose;\n* Combined with severe or not well-controlled diseases, which the investigator judges to be at greater risk of entering this study；\n* Those with a history of drug addiction or substance abuse；\n* According to the judgment of the investigator, there are concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are considered to be unsuitable for enrollment for other reasons.","ALL","18 Years","75 Years",{"count":221,"type":222},140,"ESTIMATED","INTERVENTIONAL",[225],"PHASE1","TQB3107 is an target inhibitor that binds to target to induce apoptosis and inhibits the proliferation of a variety of tumor cells. This is a clinical study to evaluate the safety and tolerability of TQB3107 tablets in subjects with advanced malignancies, to determine dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) (if any), and the recommended dose for Phase II (RP2D).",[228],"Advanced Cancers","2026-07-28",{"date":231,"type":232},"2026-07-29","ACTUAL",{"date":234,"type":232},"2024-06-27",{"date":236,"type":222},"2027-06",{"name":5,"class":6},12]